Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2021 / N 2

Оценка прогностической значимости отдельных показателей у пациентов с COVID-19 на различных этапах наблюдения
А.А. Визель, Д.И. Абдулганиева, В.Д. Федотов, А.В. Жестков, Р.Ф. Хамитов, Н.Э. Костина, Е.А. Соболева, И.Ю. Визель, Н.Г. Шамсутдинова, А.А. Туличев, Д.Ю. Константинов, Е.И. Темник, А.Ф. Молоствова, Л.М. Салимова, Р.Р. Имамутдинов, Э.Р. Абызова, Г.Ф. Хуснутдинова, К.В. Вендеревская, Е.В. Сушенцова, Н.Н. Гусева, Л.И. Хайруллина, Л.А. Визель

References

1. Ministry of Health of the Russian Federation. Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 11 (07.05.2021). Available from: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/872/attach/Bmr_COVID-19_compressed.pdf Accessed 2022 Jan 20 (In Russian).
2. Vizel AA, Abdulganiyeva DI, Bayaliyeva AD, Vanyushin AA, Salakhova IN, Vafina AR, Kolesnikov PE, Sushentsova EV, Sagdiyeva MK, Soboleva EA, Vizel IYu. Analysis of the management of patients with novel COVID-19 infection: experience of the first 5 months. Practical Pulmonology 2020;3:61-72 (In Russian).
3. Zabolotskikh IB, Zybin KB, Noskov AA, Kuznetsova MP, Musayeva TS, Sinkov SV. REMS, NEWS and qSOFA scales comparison in prognostic values of mortality among patients with COVID-19, virus identified: retrospective observational study results. Russian Journal of Anaesthesiology and Reanimatology 2020;6-2:20-6 (In Russian).
4. Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, Quartagno M, Nair A, Lipman M, Abubakar I, van Smeden M, Wong WK, Williams B, Noursadeghi M; UCLH COVID-19 Reporting Group. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. The European Respiratory Journal 2020 Dec;56(6):2003498.
5. African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. The Lancet 2021 May;397(10288):1885-94.
6. Musayeva TS, Mirtskhulava NG, Zybin KD, Sinkov SV, Astakhova EO, Lobur EI, Noskov AA, Zabolotskikh IB. Validity of qSOFA, NEWS and REMS scales in patients with COVID-19, virus not identified: retrospective observational study results. Russian Journal of Anaesthesiology and Reanimatology 2020;6-2:27-32 (In Russian).
7. Zagrebneva AI, Baryakh EA, Zhelnova EI, Poteshkina NG, Beloglazova IP, Mutovina ZYu, Samsonova IV, Kovalevskaya EA, Parshin VV, Pshenichnikova VV, Fomina DS, Kruglova TS, Lysenko MA, Dranitsyna MA. Baricitinib in treatment of patients with COVID-19: review of international data and analysis of clinical results in the Russian population. Antibiotics and Chemotherapy 2021;66(1-2):47-56 (In Russian).
8. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology 2020 Jun;127:104370.
9. Hinks TSC, Cureton L, Knight R, Wang A, Cane JL, Barber VS, Black J, Dutton SJ, Melhorn J, Jabeen M, Moss P, Garlapati R, Baron T, Johnson G, Cantle F, Clarke D, Elkhodair S, Underwood J, Lasserson D, Pavord ID, Morgan S, Richards D. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. The Lancet. Respiratory Medicine 2021 Oct;9(10):1130-40.
10. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of hydroxychloroquine in hospitalized patients with Covid-19. The New England Journal of Medicine 2020 Nov;383(21):2030-40.
11. Martin AJ, Shulder S, Dobrzynski D, Quartuccio K, Pillinger KE. Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients. Journal of Pharmacy Practice 2021 Jul;8971900211030248. Online ahead of print.
12. Putot A, Bouiller K, Laborde C, Gilis M, Févre A, Hacquin A, Manckoundia P, Hoefler F, Bermejo M, Mendes A, Serratrice C, Prendki V, Sanchez S. Association between early antibiotic therapy and in-hospital mortality among older patients with SARS-CoV-2 pneumonia. The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 2021 Jul;glab209.
13. Sreenath K, Batra P, Vinayaraj EV, Bhatia R, SaiKiran K, Singh V, Singh S, Verma N, Singh UB, Mohan A, Bhatnagar S, Trikha A, Guleria R, Chaudhry R. Coinfections with other respiratory pathogens among patients with COVID-19. Microbiology Spectrum 2021 Sep;9(1):e0016321.
14. Chocron R, Galand V, Cellier J, Gendron N, Pommier T, Bory O, Khider L, Trimaille A, Goudot G, Weizman O, Alsac JM, Geneste L, Schmeltz A, Panagides V, Philippe A, Marsou W, Ben Abdallah I, Deney A, El Batti S, Attou S, Juvin P, Delmotte T, Messas E, Pezel T, Planquette B, Duceau B, Gaussem P, Sutter W, Sanchez O, Waldman V, Diehl JL, Mirault T, Bonnet G, Cohen A, Smadja DM; Critical COVID-19 France Investigators. Anticoagulation before hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. Journal of the American Heart Association 2021 Apr;10(8):e018624.
15. Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, Gaga M. Can steroids reverse the severe COVID-19 induced “cytokine storm”? Journal of Medical Virology 2020 Nov;92(11):2866-9.
16. Fedotov VD, Tulichev AA, Fedotova OO, Dobrotina IS, Shakurova DN. Coronavirus pandemic: experience of the first wave in the Nizhny Novgorod region. The Bulletin of Contemporary Clinical Medicine 2021;14(2):39-45 (In Russian).
17. Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’ BMJ Open Respiratory Research 2020 Sep;7(1):e000724.
18. Vadász I, Husain-Syed F, Dorfmüller P, Roller FC, Tello K, Hecker M, Morty RE, Gattenlöhner S, Walmrath HD, Grimminger F, Herold S, Seeger W. Severe organising pneumonia following COVID-19. Thorax 2021 Feb;76(2):201-4.
19. Furgała-Wojas A, Kowalska M, Nowaczyk A, Fijałkowski Ł, Sałat K. Comparison of bromhexine and its active metabolite – ambroxol as potential analgesics reducing oxaliplatin-induced neuropathic pain – pharmacodynamic and molecular docking studies. Current Drug Metabolism 2020;21(7):548-61.
20. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. European Journal of Medical Research 2008;13(12):557-62.
21. Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion transport modulators differentially modulate inflammatory responses in THP-1-derived macrophages. Journal of Immunology Research 2021 Apr;2021:8832586.
22. Alkotaji M. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. International Journal of Antimicrobial Agents 2020 Dec;56(6):106192.
23. Carpinteiro A, Gripp B, Hoffmann M, Pöhlmann S, Hoertel N, Edwards MJ, Kamler M, Kornhuber J, Becker KA, Gulbins E. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. The Journal of Biological Chemistry 2021 Jan-Jun;296:100701.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]